Novartis Heart Drug Gets Endorsed by NICE, But Not for Everyone

  • Entresto backed for about 100,000 people with heart failure
  • Patients must first take hypertension drugs, NICE rules

A Novartis AG heart drug that’s struggled to gain acceptance in the U.S. won the backing of a U.K. panel as a cost-effective treatment, even without a price discount.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.